Army backs further development of rapid transfusion-transmitted disease tests

10/21/2013 | Genetic Engineering & Biotechnology News

An Army contract worth an additional $1.917 million will support MedMira's continued development of the Reveal Rapid Hepatitis B Surface Antigen Test and Multiplo Rapid HBc/HIV/HCV Antibody Test. The tests are being developed for frontline military medical uses, plus humanitarian and disaster relief efforts, according to MedMira.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care